This page uses content from Wikipedia and is licensed under CC BY-SA.


Lilopristone skeletal.svg
Clinical data
Other namesZK-98734; ZK-734; 11β-(4-(Dimethylamino)phenyl)-17β-hydroxy-17α-((Z)-3-hydroxypropenyl)estra-4,9-dien-3-one
CAS Number
PubChem CID
Chemical and physical data
Molar mass447.619 g/mol g·mol−1
3D model (JSmol)

Lilopristone (INN) (developmental code names ZK-98734, ZK-734) is a synthetic, steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering and was patented in 1985.[1][2][3][4] It is described as an abortifacient and endometrial contraceptive.[1][4][5] The drug differs from mifepristone only in the structure of its C17α side chain, and is said to have much reduced antiglucocorticoid activity in comparison.[6]

See also


  1. ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 733–. ISBN 978-1-4757-2085-3.
  2. ^ Rao (November 2009). Textbook of Gynaecology. Elsevier India. pp. 187–. ISBN 978-81-312-1526-5.
  3. ^ D.T. Baird; Günther Schütz; R. Krattenmacher (9 March 2013). Organ-Selective Actions of Steroid Hormones. Springer Science & Business Media. pp. 108–. ISBN 978-3-662-09153-1.
  4. ^ a b George W.A Milne (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 23–. ISBN 978-1-351-78989-9.
  5. ^ Hemant Deshpande (12 February 2016). Practical Management of Ovulation Induction. JP Medical Ltd. pp. 29–. ISBN 978-93-5250-028-4.
  6. ^ P. F. A. Van Look; Gregorio Pérez-Palacios; World Health Organization (1994). Contraceptive research and development, 1984 to 1994: the road from Mexico City to Cairo and beyond. Oxford University Press. p. 169. ISBN 978-0-19-563630-7. [...] lilopristone, which differs from mifepristone only in the structure of the 17a side chain, is said to have a much reduced antiglucocorticoid activity (Neef et al., 1984).